Want to see SE:PILA full AI Analyst Report?

PILA PHARMA AB (PILA) Price & Analysis

1 Followers

PILA Stock Chart & Stats

kr2.20

-kr0.50(-13.33%)

At close: Mar 06 4:00 PM EST

kr2.20

-kr0.50(-13.33%)

Day’s Range― - ―

52-Week Rangekr1.02 - kr3.65

Previous CloseN/A

Volume9.62K

Average Volume (3M)235.52K

Market Cap

kr56.65M

Enterprise Valuekr46.23M

Total Cash (Recent Filing)kr15.90M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.33

Next Earnings

Aug 27, 2026

EPS Estimate

-0.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.46

Shares Outstanding45,682,120

10 Day Avg. Volume194,482

30 Day Avg. Volume235,519

Financial Highlights & Ratios

PEG Ratio-0.37

Price to Book (P/B)4.82

Price to Sales (P/S)63.25

P/FCF Ratio-7.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Zero Debt / Clean LeverageA zero-debt balance sheet materially reduces refinancing and interest-rate risk over the medium term, preserving financial flexibility. This structural strength gives management time to progress R&D or raise capital on better terms without immediate debt service pressures.

Material Equity Base ImprovementA materially larger equity base provides a capital buffer against ongoing losses and supports solvency. This strengthens near-term funding capacity for clinical development and reduces short-term liquidation risk while R&D milestones are pursued.

Focused R&D Strategy / Targeted MechanismA concentrated, science-driven pipeline focused on TRPA1 for metabolic diseases is a durable strategic asset: it creates deep technical specialization, potential IP defensibility and clearer partnership or licensing pathways for a small R&D-centric company over the medium term.

Bears Say

Persistent Negative Free Cash FlowSustained negative operating and free cash flow indicates ongoing cash burn that will require external funding until operations change. Over 2–6 months this raises dilution and funding-execution risk and can constrain the pace of clinical programs if financing is delayed.

Widening Net LossesDeepening operating losses show limited current pathway to profitability and weak operating leverage. Continued widening losses erode equity cushions and increase dependency on capital markets or partners, threatening program continuity absent material progress or cost reductions.

Very Small, Volatile Revenue BaseTiny and inconsistent revenues mean the company cannot self-fund R&D or absorb shocks. Structurally, revenue volatility limits internal cash generation and increases the strategic need to secure external financing or partnerships to sustain development programs.

PILA FAQ

What was PILA PHARMA AB’s price range in the past 12 months?

PILA PHARMA AB lowest stock price was kr1.02 and its highest was kr3.65 in the past 12 months.

What is PILA PHARMA AB’s market cap?

PILA PHARMA AB’s market cap is kr56.65M.

When is PILA PHARMA AB’s upcoming earnings report date?

PILA PHARMA AB’s upcoming earnings report date is Aug 27, 2026 which is in 33 days.

How were PILA PHARMA AB’s earnings last quarter?

PILA PHARMA AB released its earnings results on Feb 26, 2026. The company reported -kr0.369 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.369.

Is PILA PHARMA AB overvalued?

According to Wall Street analysts PILA PHARMA AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PILA PHARMA AB pay dividends?

PILA PHARMA AB does not currently pay dividends.

What is PILA PHARMA AB’s EPS estimate?

PILA PHARMA AB’s EPS estimate is -0.22.

How many shares outstanding does PILA PHARMA AB have?

PILA PHARMA AB has 45,682,120 shares outstanding.

What happened to PILA PHARMA AB’s price movement after its last earnings report?

PILA PHARMA AB reported an EPS of -kr0.369 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.83%.

Which hedge fund is a major shareholder of PILA PHARMA AB?

Currently, no hedge funds are holding shares in SE:PILA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PILA PHARMA AB

Based in Sweden, PILA PHARMA AB (publ) is a pharmaceutical firm actively engaged in clinical development. The company's principal drug, XEN-D0501, is a TRPV1 antagonist which has successfully completed two phase 2a clinical studies aimed at treating type 2 diabetes. PILA PHARMA AB (publ) was founded in 2014 and maintains its headquarters in Malmö, Sweden.